Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies

View ORCID ProfileThibault Fiolet, View ORCID ProfileAnthony Guihur, View ORCID ProfileMathieu Rebeaud, Matthieu Mulot, View ORCID ProfileYahya Mahamat-Saleh
doi: https://doi.org/10.1101/2020.06.17.20133884
Thibault Fiolet
1CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris Saclay, 94 805, Villejuif, France
2Gustave Roussy, F-94805, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thibault Fiolet
  • For correspondence: Thibault.fiolet@gustaveroussy.fr
Anthony Guihur
3Department of Plant Molecular Biology, Faculty of Biology and Medicine, University of Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anthony Guihur
Mathieu Rebeaud
3Department of Plant Molecular Biology, Faculty of Biology and Medicine, University of Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mathieu Rebeaud
Matthieu Mulot
4Laboratory of Soil Biodiversity, Faculty of Science, University of Neuchâtel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yahya Mahamat-Saleh
1CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris Saclay, 94 805, Villejuif, France
2Gustave Roussy, F-94805, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yahya Mahamat-Saleh
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Global COVID-19 deaths reached at least 400,000 fatalities. Hydroxychloroquine is an antimalarial drug that elicit immunomodulatory effects and had shown in vitro antiviral effects against SRAS-CoV-2. This drug divided opinion worldwide in the medical community but also in the press, the general public and in public health policies. The aim of this systematic review and this meta-analysis was to bring a new overview on this controversial drug and to assess whether hydroxychloroquine could reduce COVID-19 mortality risk in hospitalized patients.

Methods and Findings Pubmed, Web of Science, Cochrane Library, MedRxiv and grey literature were searched until 10 June 2020. Only studies of COVID-19 patients treated with hydroxychloroquine (with or without azithromycin) compared with a comparative standard care group and with full-text articles in English were included. Studies reporting effect sizes as Odds Ratios, Hazard Ratio and Relative Risk for mortality risk and the number of deaths per groups were included. This meta-analysis was conducted following PRISMA guidelines and registered on PROSPERO (Registration number: CRD42020190801). Independent extraction has been performed by two independent reviewers. Effect sizes were pooled using a random-effects model.

The initial search leaded to 112 articles, from which 16 articles met our inclusion criteria. 15 studies were retained for association between hydroxychloroquine and COVID-19 survival including 15,081 patients (8,072 patients in the hydroxychloroquine arm and 7,009 patients in the standard care arm with respectively, 1,578 deaths and 1,423 deaths). 6 studies were retained for hydroxychloroquine with azithromycin. Hydroxychloroquine was not significantly associated with mortality risk (pooled Relative Risk RR=0.82 (95% Confidence Interval: 0.62-1.07, I2=82, Pheterogeneity<0.01, n=15)) within hospitalized patients, nor in association with azithromycin (pooled Relative Risk RR=1.33 (95% CI: 0.92-1.92, I2=75%, Pheterogeneity<0.01, n=6)), nor in the numerous subgroup analysis by study design, median age population, published studies (vs unpublished articles), level of bias risk. However, stratified analysis by continents, we found a significant decreased risk of mortality associated with hydroxychlroquine alone but not with azithromycin among European (RR= 0.62 (95%CI: 0.41-0.93, n=7)) and Asian studies (RR=0.36 (95%CI:0.18-0.73, n=1)), with heterogeneity detected across continent (Pheterogeneity between=0.003). These finding should be interpreted with caution since several included studies had a low quality of evidence with a small sample size, a lack of adjustment on potential confounders or selection and intervention biases.

Conclusion Our meta-analysis does not support the use of hydroxychloroquine with or without azithromycin to reduce COVID-19 mortality in hospitalized patients. It raises the question of the hydroxychloroquine use outside of clinical trial. Additional results from larger randomised controlled trials are needed

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no specific fundings for this work

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

all relevant ethical guidelines have been followed for this meta-analysis

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Competing interests: All authors declare: no support from any organisation for the submitted work other than that described above; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article included in the meta-analysis

  • Abbreviations

    HCQ
    Hydroxychloroquine
    AZ
    Azithromycin
    RR
    Relative Risk
    HR
    Hazard Ratio
    OR
    Odds Ratio
    US FDA
    US Food and Drug Administration
    EMA
    European Medicine Agency
    CI
    Confidence Interval
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted June 19, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies
    Thibault Fiolet, Anthony Guihur, Mathieu Rebeaud, Matthieu Mulot, Yahya Mahamat-Saleh
    medRxiv 2020.06.17.20133884; doi: https://doi.org/10.1101/2020.06.17.20133884
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies
    Thibault Fiolet, Anthony Guihur, Mathieu Rebeaud, Matthieu Mulot, Yahya Mahamat-Saleh
    medRxiv 2020.06.17.20133884; doi: https://doi.org/10.1101/2020.06.17.20133884

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Epidemiology
    Subject Areas
    All Articles
    • Addiction Medicine (62)
    • Allergy and Immunology (144)
    • Anesthesia (47)
    • Cardiovascular Medicine (419)
    • Dentistry and Oral Medicine (72)
    • Dermatology (49)
    • Emergency Medicine (147)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (173)
    • Epidemiology (4906)
    • Forensic Medicine (3)
    • Gastroenterology (185)
    • Genetic and Genomic Medicine (689)
    • Geriatric Medicine (72)
    • Health Economics (193)
    • Health Informatics (636)
    • Health Policy (322)
    • Health Systems and Quality Improvement (209)
    • Hematology (86)
    • HIV/AIDS (157)
    • Infectious Diseases (except HIV/AIDS) (5408)
    • Intensive Care and Critical Care Medicine (333)
    • Medical Education (96)
    • Medical Ethics (24)
    • Nephrology (77)
    • Neurology (692)
    • Nursing (42)
    • Nutrition (115)
    • Obstetrics and Gynecology (128)
    • Occupational and Environmental Health (211)
    • Oncology (447)
    • Ophthalmology (140)
    • Orthopedics (36)
    • Otolaryngology (91)
    • Pain Medicine (37)
    • Palliative Medicine (18)
    • Pathology (131)
    • Pediatrics (201)
    • Pharmacology and Therapeutics (131)
    • Primary Care Research (88)
    • Psychiatry and Clinical Psychology (787)
    • Public and Global Health (1832)
    • Radiology and Imaging (328)
    • Rehabilitation Medicine and Physical Therapy (142)
    • Respiratory Medicine (257)
    • Rheumatology (87)
    • Sexual and Reproductive Health (69)
    • Sports Medicine (63)
    • Surgery (102)
    • Toxicology (23)
    • Transplantation (29)
    • Urology (38)